Published online Jul 7, 2021. doi: 10.3748/wjg.v27.i25.3901
Peer-review started: February 5, 2021
First decision: March 14, 2021
Revised: March 27, 2021
Accepted: May 21, 2021
Article in press: May 21, 2021
Published online: July 7, 2021
Processing time: 150 Days and 2.7 Hours
The proportion of young patients with colorectal cancer (CRC), especially in their 40s, is increasing worldwide.
To confirm the clinical characteristics of such patients, we planned a study comparing them to patients in their 30s and 50s.
Patients undergoing primary resection for CRC, patients in their 30s, 40s and 50s were included in the study. Patient and tumor characteristics, and perioperative and oncologic outcomes were compared.
Most clinical characteristics of 451 (10.5%) patients in their 40s were more similar to those of patients in their 30s than those in their 50s. On pathology data, there were more metastatic lesions (30s vs 40s vs 50s; 17.5% vs 21.1% vs 14.9%, P = 0.012) in patients in their 40s. There was a trend toward less frequent K-ras mutations among patients in their 40s (48.5% vs 33.3% vs 44.5%, P = 0.064). The proportion of patients receiving postoperative chemotherapy was also significantly greater among patients in their 40s (58.3% vs 63.9% vs 56.3%, P = 0.032). Five-year overall survival (OS) and disease-free survival (DFS) did not differ between the three groups (5-year OS, 92.2% vs 89.8% vs 92.2%, P = 0.804; 5-year total DFS, 98.6% vs 95.7% vs 96.1%, P = 0.754; 5-year local DFS, 98.6% vs 94.3% vs 94.9%, P = 0.579; 5-year systemic DFS, 86.4% vs 87.9 % vs 86.4%, P = 0.908).
Patients with CRC in their 40s showed significantly more numerous metastatic lesions. The oncologic outcome of stage 1-3 patients in their 40s was not inferior compared to that of those in their 30s and 50s.
Core Tip: The age at which colorectal cancer is first diagnosed is decreasing worldwide, and colorectal cancer, especially in the 40s is very important. In our study, we found that colorectal cancer patients in their 40s had significantly more metastatic lesions and fewer K-ras mutations. Nevertheless, the oncologic outcome was never inferior compared to patients in their 30s and 50s by stages. We believe this to be a very important clinical message in the current situation.